Literature DB >> 16918268

Frequency of undiagnosed and untreated diabetes mellitus in patients with acute coronary syndromes.

D G Conaway1, J H O'Keefe.   

Abstract

The current epidemic of obesity warrants aggressive screening for associated comorbid conditions; namely, the metabolic syndrome and diabetes mellitus. Approximately 25-30% of patients with acute coronary syndrome have diabetes. Of the remaining patients, most have a spectrum of abnormal glucose metabolism, including previously undiagnosed impaired fasting glucose and diabetes mellitus. This article reviews the current literature and the author's own experience of this subject, as well as highlighting effective new agents in treating diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918268     DOI: 10.1586/14779072.4.4.503

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  3 in total

1.  Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention.

Authors:  Revathi Balakrishnan; Jeffrey S Berger; Lisa Tully; Anish Vani; Binita Shah; Joseph Burdowski; Edward Fisher; Arthur Schwartzbard; Steven Sedlis; Howard Weintraub; James A Underberg; Ann Danoff; James A Slater; Eugenia Gianos
Journal:  Diabetes Metab Res Rev       Date:  2015-05-12       Impact factor: 4.876

2.  Undiagnosed Impaired Glucose Tolerance and Type-2 Diabetes in Acute Myocardial Infarction Patients: Fequency, Characteristics and Long-Term Mortality.

Authors:  Timo Schmitz; Eva Harmel; Margit Heier; Annette Peters; Jakob Linseisen; Christa Meisinger
Journal:  Front Cardiovasc Med       Date:  2022-04-25

3.  Impact of Admission Glucose on Non-Diabetic Patients with ST-Segment Elevation Myocardial Infarction Treated with Percutaneous Coronary Intervention: A Meta-Analysis.

Authors:  Zhen-Xuan Hao; Yang Liu; Dan-Li Wang; Wen-Jie Han; Lei Wu; Heng-Liang Liu
Journal:  Acta Cardiol Sin       Date:  2016-03       Impact factor: 2.672

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.